30 Participants Needed

Olanzapine-samidorphan + Exercise for Bipolar Disorder

JT
MM
Overseen ByMegan Mayer, BA
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: New York State Psychiatric Institute
Must be taking: Antipsychotics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination treatment of olanzapine-samidorphan (a medication that helps manage mental health symptoms) and aerobic exercise for individuals with schizophrenia, schizoaffective disorder, or bipolar disorder. The aim is to determine if this combination can improve symptoms and overall well-being for those who haven't found relief with other treatments. The trial seeks participants with these conditions who have experienced limited success with their current medications or are interested in trying a structured exercise program. As a Phase 4 trial, this research aims to understand how this already FDA-approved and effective treatment can benefit more patients.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot take certain medications like opioid agonists or antagonists before and during the study. It's best to discuss your current medications with the trial team to see if they are allowed.

What is the safety track record for olanzapine-samidorphan plus exercise?

Research has shown that olanzapine-samidorphan is safe and well-tolerated over the long term. In studies lasting up to four years, patients maintained symptom control without major safety issues. One study found that after one year, it was generally well-tolerated, and patients' weight and overall health remained stable. These findings suggest that olanzapine-samidorphan consistently remains safe for many people over time.12345

Why are researchers enthusiastic about this study treatment?

Olanzapine-samidorphan is unique because it combines two active ingredients to tackle bipolar disorder with fewer side effects. Traditional treatments like lithium or valproate often come with weight gain and metabolic issues. However, olanzapine-samidorphan pairs an antipsychotic with samidorphan, which helps reduce these side effects while maintaining efficacy. Researchers are excited about this treatment because it offers a more balanced approach, potentially improving patient adherence and overall outcomes.

What evidence suggests that olanzapine-samidorphan plus exercise might be an effective treatment for bipolar disorder?

Research has shown that the combination of olanzapine and samidorphan (Olz/Sam) effectively manages symptoms in people with schizophrenia and bipolar I disorder. Studies have demonstrated that this treatment can control symptoms for several years. Specifically, one study found that patients required fewer emergency healthcare visits after starting this treatment. This combination aims to reduce the weight gain often associated with olanzapine alone. Overall, this treatment has been well-tolerated and helps maintain symptom control over the long term. Participants in this trial will receive olanzapine-samidorphan combined with an exercise regimen to evaluate its effectiveness for bipolar disorder.23678

Are You a Good Fit for This Trial?

This trial is for individuals with schizophrenia, schizoaffective disorder, or bipolar I/II/NOS. Participants will engage in an 8-week treatment with Olanzapine-samidorphan (Olz/Sam) combined with a 4-week aerobic exercise program.

Inclusion Criteria

Body Mass Index (BMI) of 18.0-40.0 kg/m2 at Visits 1 and 2
Willing to provide informed consent at Visit 1
I have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder.
See 5 more

Exclusion Criteria

I do not have any health conditions that could worsen with study treatment.
I have a bowel condition that has caused me to lose weight.
Positive drug screen for opioids, phencyclidine, amphetamine/methamphetamine, or cocaine at Visit 1 or Visit 2
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants receive 8 weeks of open label Olz/Sam, with 4 weeks of aerobic exercise

8 weeks
Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Olanzapine-samidorphan
Trial Overview The study tests the combination of Olz/Sam medication and aerobic exercise to see how they work together in treating patients with certain psychiatric disorders over a period of eight weeks at a single site.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: olanzapine-samidorphan plus exerciseExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

New York State Psychiatric Institute

Lead Sponsor

Trials
481
Recruited
154,000+

Published Research Related to This Trial

The olanzapine/samidorphan (OLZ/SAM) combination treatment significantly reduces the risk of clinically significant weight gain (>10%) compared to olanzapine (OLZ) monotherapy in adults with schizophrenia, with an odds ratio of 0.50.
OLZ/SAM maintains similar clinical efficacy to OLZ while improving tolerability, indicating it may be a preferable option for managing schizophrenia without the added risk of significant weight gain.
Olanzapine and samidorphan combination treatment: A systematic review.Jawad, MY., Alnefeesi, Y., Lui, LMW., et al.[2022]
In a 52-week study involving 281 patients with schizophrenia, the combination of olanzapine and samidorphan (OLZ/SAM) was generally well tolerated, with most patients completing the treatment and showing sustained improvement in schizophrenia symptoms as measured by PANSS and CGI-S scores.
While there was a mean weight increase of 1.86 kg over the year, this change stabilized early in the treatment, suggesting that OLZ/SAM may effectively mitigate the weight gain typically associated with olanzapine.
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.Yagoda, S., Graham, C., Simmons, A., et al.[2022]
The combination of olanzapine and samidorphan (OLZ/SAM) effectively treats schizophrenia while significantly reducing the weight gain side effects commonly associated with olanzapine alone, based on studies involving approximately 960 patients.
OLZ/SAM has been approved for treating bipolar I disorder and offers advantages such as once-daily dosing and improved tolerability, which may enhance patient adherence to treatment.
Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.Pham, H., Warlick, H., Bermudez, R., et al.[2023]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40465200/
Healthcare Resource Utilization 6 Months Before and After ...Olanzapine is an effective medication for people with schizophrenia (SZ) or bipolar I disorder (BD-I), but it causes significant weight gain for ...
Long-Term Safety, Tolerability, and Durability of Treatment ...During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients' symptoms remained ...
Efficacy & SafetyExplore olanzapine efficacy and safety data that provided the basis for the bipolar I disorder indication for LYBALVI.1. See Bipolar I Disorder Data ...
Long-Term Data On Olanzapine and Samidorphan ...The combination of olanzapine and samidorphan (OLZ/SAM, Lybalvi; Alkermes) maintained symptom control over 4 years for individuals with schizophrenia.
Real-World Assessment of Patients With Bipolar I DisorderOLZ/SAM treatment was associated with significant reductions in acute healthcare resource utilization (HCRU) in a previous 6-month pre/post study. This study ...
6.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39630083/
Long-Term Safety, Tolerability, and Durability of Treatment ...Conclusion: OLZ/SAM maintained symptom control with a long-term safety profile over 4 years consistent with that of prior studies. Trials ...
A phase 3, multicenter study to assess the 1-year safety ...OLZ/SAM was generally well tolerated over 52 weeks. Weight, waist circumference, metabolic laboratory parameters, and schizophrenia symptoms remained stable ...
Press ReleasesResults demonstrated that LYBALVI was generally well tolerated with stability of body weight and metabolic profile, and durable symptom control, for up to four ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security